Rugvænget 5
Ansager 6823
Denmark
45 69 16 03 93
https://www.dancann.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 12
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Jeppe Krog Rasmussen | Founder, Member of Executive Board, Director & CEO | N/D | N/D | 1995 |
Mr. Peter Hauberg Sondergaard | Chief Financial Officer | N/D | N/D | 1972 |
Mr. Jens Markussen | Head of Production | N/D | N/D | N/D |
Mr. John Morell Frellsen | Chief Commercial Officer | N/D | N/D | N/D |
Ms. Charlotte Hagedorn Jorgensen | Head of Quality Assurance | N/D | N/D | N/D |
DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company's development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 CannGros, FLS04 CannGros, and FLS05 CannGros. It is also involved in the import and distribution of Bedrocan CannGros, Bedica CannGros, and Bediol CannGros. The company was incorporated in 2018 and is based in Ansager, Denmark.
La calificación ISS Governance QuickScore de DanCann Pharma A/S a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.